Patent portfolio
Biomarker and diagnostics portfolio
- Prognostic and Diagnostic Glycan-based Biomarkers of Brain Damage
- European patent No. 3283880
- US patent No. 10,739,335
- Canadian patent No. 2,982,503
- Israeli patent No. 254 980
- Non-invasive Brain Injury Diagnostic Device
- PCT application WO/2018/154,401, has entered into national phases
- South African patent (number pending)
- Utility model granted in China and Australia
- Device and Method for Detecting of Brain injury in a Subject
- PCT application WO 2021/099677
Australian innovation patent No. 2020104474
- Finnish Utility model No. 13179
- A Method for Determining a Lectin-binding Glycan Indicative To Traumatic Brain Injury
- PCT application WO 2021/205059
- European patent No. 4133279
- A Method for Diagnosis of Traumatic Brain Injury
- PCT-application WO 2023/161557
- Finnish patent No. 130340
- Method of Detecting Tissue Damage
- PCT-application WO 2023/161553
- Finnish patent No. 130428
- Divisional Finnish patent No. 130798
- A Hand-held Liquid Sample Collection and Testing Device
- Finnish utility model No. 13331
- German utility model No. 20 2023 100 246
- Austrian utility model pending
Drug development portfolio
- Multivalent Compounds for Use in the Treatment and Prevention of Brain Damage
- US patent No. 9,975,846
- Finnish patent No. 127024
- Israeli patent No. 251407
- European patent No. 3201173
- Conjugates and Conjugates for Use in Preventing or Treating of Brain Damage and Neurodegenerative Diseases
- PCT application WO 2021/038125
- Finnish patent No. 130262
Other patents
- Method for Determining Coronavirus and Kit for the Same
- PCT application WO 2021/205058
- European patent No. 3911956